Literature DB >> 26880235

Subclassification of fatty liver by its pathogenesis: cIEFing is believing.

Frances L Byrne1, Kyle L Hoehn1.   

Abstract

Fatty liver, also termed hepatic steatosis or fatty liver disease, is a condition characterized by excess fat accumulation in the liver. Common causes of fatty liver include obesity, ageing, medications, genetic disorders, viral hepatitis, excess alcohol or toxins. This diversity in pathogenesis is matched by an equally diverse spectrum of consequences, whereby some individuals remain asymptomatic yet others progress through a series of inflammatory, fibrotic and metabolic disorders that can lead to liver failure, cancer or diabetes. Current treatment approaches for fatty liver do not differ by disease aetiology and primarily involve weight loss strategies or management of co-morbidities. In a recent paper published in this journal, Urasaki et al used capillary isoelectric focusing (cIEF) to create profiles of protein post-translational modifications that distinguish four different models of fatty liver in mice. Importantly, this new cIEF approach has the potential to provide rapid individualized diagnosis of fatty liver pathogenesis that may enable more accurate and personalized treatment strategies. Further testing and optimization of cIEF as a diagnostic screening tool in humans is warranted.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  capillary isoelectric focusing immunoassay; fatty liver disease classification; protein post-translational modifications

Mesh:

Substances:

Year:  2016        PMID: 26880235      PMCID: PMC4890598          DOI: 10.1002/path.4702

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  10 in total

1.  The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Anna Mae Diehl; Elizabeth M Brunt; Kenneth Cusi; Michael Charlton; Arun J Sanyal
Journal:  Hepatology       Date:  2012-06       Impact factor: 17.425

Review 2.  Histopathology of nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Dina G Tiniakos
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

3.  Molecular classification of fatty liver by high-throughput profiling of protein post-translational modifications.

Authors:  Yasuyo Urasaki; Ronald R Fiscus; Thuc T Le
Journal:  J Pathol       Date:  2016-02-25       Impact factor: 7.996

4.  Prevalence of fatty liver in children and adolescents.

Authors:  Jeffrey B Schwimmer; Reena Deutsch; Tanaz Kahen; Joel E Lavine; Christina Stanley; Cynthia Behling
Journal:  Pediatrics       Date:  2006-10       Impact factor: 7.124

Review 5.  Non-alcoholic fatty liver disease: The diagnosis and management.

Authors:  Shehab M Abd El-Kader; Eman M Salah El-Den Ashmawy
Journal:  World J Hepatol       Date:  2015-04-28

Review 6.  Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.

Authors:  G Vernon; A Baranova; Z M Younossi
Journal:  Aliment Pharmacol Ther       Date:  2011-05-30       Impact factor: 8.171

7.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

Review 8.  Obesity-associated liver disease.

Authors:  Giulio Marchesini; Simona Moscatiello; Silvia Di Domizio; Gabriele Forlani
Journal:  J Clin Endocrinol Metab       Date:  2008-11       Impact factor: 5.958

9.  Secondary causes of nonalcoholic fatty liver disease.

Authors:  Jacob M Kneeman; Joseph Misdraji; Kathleen E Corey
Journal:  Therap Adv Gastroenterol       Date:  2012-05       Impact factor: 4.409

Review 10.  Non-alcoholic fatty liver disease.

Authors:  Naveed Sattar; Ewan Forrest; David Preiss
Journal:  BMJ       Date:  2014-07-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.